Study of NGX267 Oral Capsules in Patients With Xerostomia Associated With Sjorgren's Syndrome
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness of NGX267 in the improvement of
decreased salivary flow associated with primary or secondary Sjögren's syndrome.
For each patient, the study includes four periods of treatment separated by a washout period
that may range from 4 - 8 days according to patient and site discretion. Each treatment
period includes two overnight stays in the clinic. One dose of study drug is taken during
each treatment period